en

Sign up
Investments involve risks and are not suitable for all investors.
Home・Stock List・AstraZeneca PLC
Search

AstraZeneca PLC

Closed

Sector Healthcare

11,564 -0.58

Buy

Price update 29 Oct 2024, 16:29 UTC

BuySell

Overview

Share price change

24h

Current

Min

11556

Max

11714

Key metrics

By Trading Economics

Income

-252M

1.9B

Sales

258M

13B

P/E

Sector Avg

38.58

112.16

EPS

1.98

Profit margin

14.894

EBITDA

-349M

4.1B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+18.06 upside

Dividends

By Dow Jones

Next Earnings

12 Nov 2024

Market Stats

By TradingEconomics

Market Cap

992M

187B

Previous open

11564.58

Previous close

11564

News Sentiment

By Acuity

30%

70%

106 / 389 Healthcare

AstraZeneca PLC Chart

Past performance is not a reliable indicator of future results.

Related News

10 Sept 2024, 09:29 UTC

Major Market Movers

AstraZeneca Shares Slump After Cancer Drug Misses Key Target

DJ

Read

25 Jul 2024, 09:17 UTC

Earnings

AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update

DJ

Read

25 Jul 2024, 06:48 UTC

Earnings

AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations

DJ

Read

12 Sept 2024, 17:01 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

DJ

Read

12 Sept 2024, 11:00 UTC

Top News

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

DJ

Read

10 Sept 2024, 13:08 UTC

Market Talk

AstraZeneca's Lung Cancer Drug Candidate Disappoints, Lowering Probability of FDA Approval -- Market Talk

DJ

Read

9 Sept 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

DJ

Read

5 Sept 2024, 13:00 UTC

Top News

China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ

DJ

Read

29 Jul 2024, 10:30 UTC

Top News

Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ

DJ

Read

25 Jul 2024, 13:20 UTC

Earnings

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

DJ

Read

25 Jul 2024, 09:21 UTC

Market Talk
Earnings

AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk

DJ

Read

25 Jul 2024, 07:05 UTC

Market Talk
Earnings

AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk

DJ

Read

25 Jul 2024, 06:06 UTC

Earnings

AstraZeneca Increased Interim Dividend by 7c to $1.00

DJ

Read

25 Jul 2024, 06:04 UTC

Earnings

AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Read

25 Jul 2024, 06:04 UTC

Earnings

AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range

DJ

Read

25 Jul 2024, 06:04 UTC

Earnings

AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Read

25 Jul 2024, 06:04 UTC

Earnings

AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency

DJ

Read

25 Jul 2024, 06:03 UTC

Earnings

AstraZeneca Raises 2024 View

DJ

Read

25 Jul 2024, 06:02 UTC

Earnings

AstraZeneca 2Q Revenue Consensus Was $12.7B

DJ

Read

25 Jul 2024, 06:02 UTC

Earnings

AstraZeneca 2Q Core EPS Consensus Was $1.95

DJ

Read

25 Jul 2024, 06:00 UTC

Earnings

AstraZeneca PLC 2Q Adj EPS $1.98

DJ

Read

25 Jul 2024, 06:00 UTC

Earnings

AstraZeneca PLC 2Q Pretax Pft $2.4B

DJ

Read

25 Jul 2024, 06:00 UTC

Earnings

AstraZeneca PLC 2Q Rev $12.94B

DJ

Read

25 Jul 2024, 06:00 UTC

Earnings

AstraZeneca PLC 2Q Oper Pft $2.75B

DJ

Read

25 Jul 2024, 06:00 UTC

Earnings

AstraZeneca PLC 2Q Net Pft $1.93B

DJ

Read

25 Jul 2024, 06:00 UTC

Earnings

AstraZeneca PLC 2Q EPS $1.24

DJ

Read

15 Jul 2024, 06:04 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Read

15 Jul 2024, 06:04 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone

DJ

Read

15 Jul 2024, 06:02 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing

DJ

Read

15 Jul 2024, 06:02 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B

DJ

Read

AstraZeneca PLC Forecast

Price Target

By TipRanks

18.06% upside

12 Months Forecast

Average 13,701.56 GBX  18.06%

High 20,000 GBX

Low 10,500 GBX

Based on 14 Wall Street analysts offering 12 month price targets forAstraZeneca PLC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

14 ratings

9

Buy

2

Hold

3

Sell

Based on 14 analysts giving stock ratings to AstraZeneca PLC - Dist in the past 3 months.

Sentiment

By Acuity

106 / 389 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

$

About AstraZeneca PLC

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.